OTCM
ELLXF
Market cap2mUSD
Oct 08, Last price
0.00USD
1D
28.65%
1Q
-59.26%
IPO
-99.66%
Name
Elixinol Wellness Ltd
Chart & performance
P/E
—
P/S
0.17
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.12%
Rev. gr., 5y
0.64%
Revenues
16m
+3.64%
Net income
-6m
L+219.40%
CFO
-3m
L-7.35%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Elixinol Wellness Limited, an Australian-based company established in 2017 with its headquarters in Sydney, operates as a global producer and supplier of hemp-derived products. The firm crafts and distributes a diverse range of hemp-based wellness, beauty, and food items, marketed under its well-known Elixinol and Hemp Foods Australia brands. Its comprehensive product portfolio encompasses cannabidiol (CBD) products, dietary supplements, various food items, topicals, and skincare solutions. These offerings reach consumers across significant international markets, including the Americas, Europe, and Australia. The company officially adopted its current name, Elixinol Wellness Limited, in May 2021, having previously been known as Elixinol Global Limited.
Key people
Ron Dufficy
Global Chief Financial Officer · since 2019
Ali Atcha
Chief Executive Officer of Europe & UK · since 2019
Leif Harrison
Chief Executive Officer of America · since 2019
Greg Smith
Global Chief Information Officer · since 2019
Gabriel Ettenson
General Manager - Elixinol US
Teresa Cleary
Global General Counsel, Company Secretary · since 2019
IPO date
Jan 08, 2018
Employees
Domiciled in
AU
Incorporated in
AU
Legal address
c/o Company Matters Pty Limited
Level 12
680 George Street
Sydney, NSW 2000
AU
Level 12
680 George Street
Sydney, NSW 2000
AU
Headquarters
Level 36
1 Macquarie Place
Sydney, NSW 2000
AU
1 Macquarie Place
Sydney, NSW 2000
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||